Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2007 4
2008 2
2009 4
2010 3
2011 2
2012 2
2013 2
2014 1
2016 2
2017 2
2018 1
2019 5
2021 4
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Targeting LIF/LIFR signaling in cancer.
Viswanadhapalli S, Dileep KV, Zhang KYJ, Nair HB, Vadlamudi RK. Viswanadhapalli S, et al. Among authors: nair hb. Genes Dis. 2021 Apr 29;9(4):973-980. doi: 10.1016/j.gendis.2021.04.003. eCollection 2022 Jul. Genes Dis. 2021. PMID: 35685476 Free PMC article. Review.
The LIFR Inhibitor EC359 Effectively Targets Type II Endometrial Cancer by Blocking LIF/LIFR Oncogenic Signaling.
Spencer N, Rodriguez Sanchez AL, Gopalam R, Subbarayalu P, Medina DM, Yang X, Ramirez P, Randolph L, Aller EJ, Santhamma B, Rao MK, Tekmal RR, Nair HB, Kost ER, Vadlamudi RK, Viswanadhapalli S. Spencer N, et al. Among authors: nair hb. Int J Mol Sci. 2023 Dec 13;24(24):17426. doi: 10.3390/ijms242417426. Int J Mol Sci. 2023. PMID: 38139260 Free PMC article.
Inhibition of LIFR Blocks Adiposity-Driven Endometrioid Endometrial Cancer Growth.
Blankenship L, Pratap UP, Yang X, Liu Z, Altwegg KA, Santhamma B, Ramasamy K, Konda S, Chen Y, Lai Z, Zheng S, Sareddy GR, Valente PT, Kost ER, Nair HB, Tekmal RR, Vadlamudi RK, Viswanadhapalli S. Blankenship L, et al. Among authors: nair hb. Cancers (Basel). 2022 Nov 2;14(21):5400. doi: 10.3390/cancers14215400. Cancers (Basel). 2022. PMID: 36358818 Free PMC article.
LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer.
Li M, Viswanadhapalli S, Santhamma B, Pratap UP, Luo Y, Liu J, Altwegg KA, Tang W, Liu Z, Li X, Ebrahimi B, Yan H, Zou Y, Konda S, Sareddy GR, Xu Z, Chen Y, Rao MK, Brenner AJ, Kaklamani VG, Tekmal RR, Ahmed G, Raj GV, Nickisch KJ, Nair HB, Vadlamudi RK. Li M, et al. Among authors: nair hb. Commun Biol. 2021 Oct 29;4(1):1235. doi: 10.1038/s42003-021-02741-7. Commun Biol. 2021. PMID: 34716410 Free PMC article.
LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer.
Tang W, Ramasamy K, Pillai SMA, Santhamma B, Konda S, Pitta Venkata P, Blankenship L, Liu J, Liu Z, Altwegg KA, Ebrahimi B, Pratap UP, Li X, Valente PT, Kost E, Sareddy GR, Vadlamudi RK, Nair HB, Tekmal RR, Viswanadhapalli S. Tang W, et al. Among authors: nair hb. Cell Death Discov. 2021 Aug 16;7(1):216. doi: 10.1038/s41420-021-00603-z. Cell Death Discov. 2021. PMID: 34400617 Free PMC article.
Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling.
Singhal H, Greene ME, Zarnke AL, Laine M, Al Abosy R, Chang YF, Dembo AG, Schoenfelt K, Vadhi R, Qiu X, Rao P, Santhamma B, Nair HB, Nickisch KJ, Long HW, Becker L, Brown M, Greene GL. Singhal H, et al. Among authors: nair hb. Oncotarget. 2017 Sep 28;9(4):4282-4300. doi: 10.18632/oncotarget.21378. eCollection 2018 Jan 12. Oncotarget. 2017. PMID: 29435103 Free PMC article.
36 results